Stocks
Guardant Health Financial Statements (GH) |
||||||||||
| Guardant Healthsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 25.02.2021 | 24.02.2022 | 23.02.2023 | 22.02.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 214.4 | 286.7 | 373.7 | 449.5 | 563.9 | 692.3 | |||
| Operating Income, bln rub | -82.4 | -255.0 | -411.0 | -544.4 | -564.7 | -515.1 | ||||
| EBITDA, bln rub | ? | -54.9 | -225.1 | -359.6 | -614.9 | -433.3 | -487.8 | |||
| Net profit, bln rub | ? | -67.9 | -246.3 | -384.8 | -654.6 | -479.4 | -512.4 | |||
| OCF, bln rub | ? | -47.1 | -103.9 | -209.0 | -309.5 | -325.0 | -254.1 | |||
| CAPEX, bln rub | ? | 21.3 | 54.1 | 75.0 | 77.5 | 20.5 | 20.3 | |||
| FCF, bln rub | ? | -68.4 | -158.0 | -284.1 | -386.9 | -345.5 | -274.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 21.2 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.14% | ||||
| OPEX, bln rub | 226.0 | 449.1 | 661.7 | 837.6 | 901.6 | 1 076 | ||||
| Cost of production, bln rub | 70.7 | 92.5 | 122.9 | 156.3 | 227.1 | 293.3 | ||||
| R&D, bln rub | 86.3 | 149.9 | 263.2 | 373.8 | 367.2 | 344.1 | ||||
| Interest expenses, bln rub | 1.18 | 4.77 | 2.58 | 2.58 | 2.58 | 2.58 | ||||
| Assets, bln rub | 962.5 | 2 272 | 2 204 | 1 610 | 1 786 | 1 539 | ||||
| Net Assets, bln rub | ? | 798.4 | 1 298 | 645.0 | 60.2 | 158.7 | -60.1 | |||
| Debt, bln rub | 33.3 | 847.9 | 1 361 | 1 369 | 1 354 | 1 339 | ||||
| Cash, bln rub | 522.8 | 1 795 | 932.7 | 1 011 | 1 169 | 999.1 | ||||
| Net debt, bln rub | -489.5 | -947.0 | 428.1 | 358.1 | 185.1 | 340.3 | ||||
| Ordinary share price, rub | 78.1 | 128.9 | 100.0 | 27.2 | 27.1 | 26.9 | ||||
| Number of ordinary shares, mln | 90.6 | 97.5 | 101.3 | 102.2 | 112.0 | 123.1 | ||||
| Market cap, bln rub | 7 079 | 12 566 | 10 133 | 2 779 | 3 029 | 3 308 | ||||
| EV, bln rub | ? | 6 590 | 11 619 | 10 562 | 3 137 | 3 214 | 3 648 | |||
| Book value, bln rub | 780 | 1 279 | 628 | 45 | 146 | -71 | ||||
| EPS, rub | ? | -0.75 | -2.53 | -3.80 | -6.41 | -4.28 | -4.16 | |||
| FCF/share, rub | -0.76 | -1.62 | -2.80 | -3.79 | -3.08 | -2.23 | ||||
| BV/share, rub | 8.61 | 13.1 | 6.19 | 0.44 | 1.31 | -0.57 | ||||
| EBITDA margin, % | ? | -25.6% | -78.5% | -96.2% | -136.8% | -76.8% | -70.5% | |||
| Net margin, % | ? | -31.7% | -85.9% | -103.0% | -145.6% | -85.0% | -74.0% | |||
| FCF yield, % | ? | -0.97% | -1.26% | -2.80% | -13.9% | -11.4% | -8.29% | |||
| ROE, % | ? | -8.50% | -19.0% | -59.7% | -1 088% | -302.1% | 852.7% | |||
| ROA, % | ? | -7.05% | -10.8% | -17.5% | -40.7% | -26.8% | -33.3% | |||
| P/E | ? | -104.3 | -51.0 | -26.3 | -4.25 | -6.32 | -6.46 | |||
| P/FCF | -103.5 | -79.5 | -35.7 | -7.18 | -8.77 | -12.1 | ||||
| P/S | ? | 33.0 | 43.8 | 27.1 | 6.18 | 5.37 | 4.78 | |||
| P/BV | ? | 9.08 | 9.83 | 16.1 | 61.5 | 20.7 | -46.8 | |||
| EV/EBITDA | ? | -120.0 | -51.6 | -29.4 | -5.10 | -7.42 | -7.48 | |||
| Debt/EBITDA | 8.91 | 4.21 | -1.19 | -0.58 | -0.43 | -0.70 | ||||
| R&D/CAPEX, % | 405.4% | 277.2% | 350.8% | 482.6% | 1 792% | 1 696% | ||||
| CAPEX/Revenue, % | 9.93% | 18.9% | 20.1% | 17.2% | 3.63% | 2.93% | ||||
| Guardant Health shareholders | ||||||||||
